M08.46 Pauciarticular juvenile rheumatoid arthritis, knee

Name of the Condition

• Pauciarticular Juvenile Rheumatoid Arthritis, Knee

Summary

Pauciarticular juvenile rheumatoid arthritis is a subtype of juvenile idiopathic arthritis characterized by inflammation in four or fewer joints during the first six months of disease onset. The "knee" designation specifies the knee joint as the site of involvement. This condition primarily affects children and adolescents, with symptoms including joint pain, swelling, and stiffness localized to the knee. Systemic features may be present but are less prominent than in other subtypes.

Causes

The exact cause is unknown, but it is believed to be an autoimmune disorder where the immune system mistakenly attacks healthy joint tissues. Genetic factors and environmental triggers may contribute to disease development, though specific triggers are not well-defined.

Risk Factors

• Age (most commonly diagnosed in children under 16).
• Female gender (higher prevalence, especially in those with ANA positivity).
• Positive antinuclear antibody (ANA) test, which increases risk of uveitis.
• Family history of autoimmune diseases.

Symptoms

• Joint pain, swelling, and stiffness in the knee, often worse in the morning.
• Reduced range of motion in the affected knee.
• Possible eye inflammation (uveitis), which may be asymptomatic initially.
• Limping or reluctance to bear weight on the affected leg.

Diagnosis

Diagnosis involves a combination of clinical evaluation, medical history, and diagnostic tests. Physical examination assesses knee joint involvement, while blood tests (e.g., inflammatory markers, ANA) and imaging (e.g., X-rays, ultrasound) may be used to confirm inflammation and rule out other conditions. Documentation of joint involvement within six months of onset is critical for classification.

Treatment Options

Treatment focuses on reducing inflammation, preserving joint function, and managing symptoms. Options may include nonsteroidal anti-inflammatory drugs (NSAIDs), intra-articular corticosteroid injections, and physical therapy. In some cases, disease-modifying antirheumatic drugs (DMARDs) or biologics may be prescribed. Regular monitoring for uveitis is recommended, especially in ANA-positive patients.

Prognosis and Follow-Up

Prognosis varies; many children achieve remission, but some may experience persistent joint damage or functional limitations. Regular follow-up with a rheumatologist is essential to monitor disease activity, adjust treatment, and screen for complications like uveitis. Early intervention improves long-term outcomes.

Complications

• Chronic joint damage or deformity.
• Uveitis (eye inflammation), potentially leading to vision loss if untreated.
• Growth disturbances in affected limbs.
• Reduced mobility or functional impairment.

Lifestyle & Prevention

• Maintain a balanced diet to support overall health.
• Engage in low-impact exercises (e.g., swimming) to preserve joint mobility.
• Protect joints during activities to avoid injury.
• Follow prescribed treatment plans consistently.

When to Seek Professional Help

Seek medical attention if symptoms worsen, new joints become involved, or signs of uveitis (e.g., eye pain, redness, sensitivity to light) occur. Prompt evaluation is critical to prevent complications.

Tips for Medical Coders

Use M08.46 for pauciarticular juvenile rheumatoid arthritis with knee involvement. Ensure documentation specifies the knee as the affected site and confirms joint involvement within six months of onset. Differentiate from other juvenile idiopathic arthritis subtypes and document any associated conditions (e.g., uveitis) separately if applicable.